Coeur D'alene, IDNCT06577441Now EnrollingIRB Ready

Myelodysplastic Syndrome Clinical Trial in Coeur D'alene, ID

Access cutting-edge myelodysplastic syndrome treatment through this clinical trial at a research site in Coeur D'alene. Study-provided care at no cost to qualified participants.

Sponsored by National Cancer Institute (NCI)

Quick Self-Assessment

See if you qualify for this Coeur D'alene location

Preparing your pre-screening questions...

Expert Care in Coeur D'alene

Access myelodysplastic syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myelodysplastic syndrome treatment provided free

Apply for This Coeur D'alene Location

Check if you qualify for this myelodysplastic syndrome clinical trial in Coeur D'alene, ID

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Coeur D'alene

    Convenient for ID residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Coeur D'alene site if eligible
  4. 4Begin participation

About This Myelodysplastic Syndrome Study in Coeur D'alene

This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

GENERAL MYLEOMATCH MSRP REGISTRATION CRITERIA:
Patients must be registered to the Master Screening and Reassessment Protocol (MSRP) and assigned to this protocol by the MATCHBox Treatment Verification Team.
Participants must not have received prior anti-cancer therapy for AML or MDS.
Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility.
Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction. The use of prior hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide is allowed.
REGISTRATION ELIGIBILITY CRITERIA (STEP 1)
Patients must have a morphologically-confirmed diagnosis of MDS with a

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Coeur D'alene?

Yes, this clinical trial (NCT06577441) has an active research site in Coeur D'alene, ID that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myelodysplastic Syndrome Treatment Options in Coeur D'alene, ID

If you're searching for myelodysplastic syndrome treatment options in Coeur D'alene, ID, this clinical trial (NCT06577441) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Coeur D'alene research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelodysplastic syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myelodysplastic syndrome clinical trials near you to find additional studies recruiting in your area.

More Myelodysplastic Syndromes Trials in Coeur D'alene, ID

See all myelodysplastic syndromes clinical trials recruiting in Coeur D'alene — not just this study.

Browse Myelodysplastic Syndromes Trials in Coeur D'alene →

Browse More Trials by Condition

Myelodysplastic Syndromes TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Coeur D'alene?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Coeur D'alene, ID